Corticosteroid Eyedrops Sales

Corticosteroid Eyedrops Sales Market Outlook

The global corticosteroid eyedrops market is anticipated to reach USD 3.6 billion by 2035, growing at a substantial CAGR of 5.8% during the forecast period from 2025 to 2035. This growth can be attributed to the increasing prevalence of eye-related conditions, such as allergic conjunctivitis and dry eye syndrome, alongside a rising awareness of the benefits of corticosteroid therapies. Additionally, advancements in drug formulation and delivery systems have contributed to the market expansion, as more effective and user-friendly eyedrop solutions are being developed. The growing geriatric population, which is more susceptible to eye disorders, further fuels demand for these medications. Moreover, the increasing adoption of online pharmacies provides better accessibility to consumers, thereby supporting market growth.

Growth Factor of the Market

Several factors contribute to the growth of the corticosteroid eyedrops market, starting with the rising incidence of ocular diseases, which necessitates effective treatment solutions. Increasing environmental factors, including pollution and allergens, have led to a higher prevalence of eye-related ailments, thereby driving the demand for corticosteroid treatments. The development of innovative and advanced formulations, including preservative-free options, caters to the needs of sensitive patients, enhancing the therapeutic effects and compliance. Additionally, the trend of self-medication has been gaining traction, particularly in over-the-counter sales of corticosteroid eyedrops, which significantly boosts market penetration. Besides, strategic collaborations among key players and ongoing research and development are expected to yield new opportunities, further fueling the market's growth potential.

Key Highlights of the Market

• The global corticosteroid eyedrops market is projected to grow at a CAGR of 5.8% from 2025 to 2035.
• Increasing prevalence of eye disorders, particularly among the aging population, drives demand for corticosteroid therapies.
• Advancements in drug formulations, including preservative-free options, improve patient compliance and treatment effectiveness.
• The rise of e-commerce and online pharmacy platforms enhances accessibility to corticosteroid eyedrops.
• Strategic collaborations and partnerships among key players are fostering innovation and expanding product offerings.

By Product Type

Dexamethasone:

Dexamethasone is a highly potent corticosteroid commonly used in the treatment of various eye conditions, including inflammation and allergic reactions. Its ability to suppress inflammation and the immune response makes it a preferred choice for ophthalmologists. The availability of dexamethasone in different formulations, including eyedrops and ointments, further enhances its usability. Additionally, the growing preference for dexamethasone among healthcare providers can be attributed to its rapid onset of action and effectiveness in treating severe ocular inflammatory conditions. The increasing adoption of this product type in clinical settings reflects its importance in managing chronic ocular diseases, which contributes to the overall growth of the corticosteroid eyedrops market.

Prednisolone:

Prednisolone, another widely used corticosteroid in ophthalmology, is effective in treating conditions such as uveitis, postoperative inflammation, and allergic conjunctivitis. Its therapeutic efficacy, combined with a favorable safety profile, makes it a popular choice for patients. Prednisolone eyedrops are available in various concentrations, allowing for flexibility in treatment regimens. The rising number of surgical procedures, including cataract surgeries, has increased the usage of prednisolone as a postoperative medication to prevent inflammation. Furthermore, healthcare practitioners' growing awareness of the benefits of this corticosteroid contributes to its demand in the corticosteroid eyedrops market.

Fluorometholone:

Fluorometholone is a soft corticosteroid that is often preferred for its lower potential for intraocular pressure elevation compared to other corticosteroids. This characteristic makes it particularly suitable for treating patients with a history of glaucoma or those who are at risk of developing intraocular pressure issues. Fluorometholone is commonly prescribed for managing inflammatory conditions of the eye, including allergic conjunctivitis and keratitis. The rising prevalence of these conditions has fueled the demand for fluorometholone eyedrops, making it an essential segment within the corticosteroid eyedrops market. Its effectiveness, combined with a reduced side-effect profile, attracts both healthcare providers and patients alike.

Loteprednol:

Loteprednol is a unique corticosteroid that exhibits a rapid onset of action and a favorable side effect profile, making it particularly effective for treating ocular inflammation. It is often used in the management of allergic conjunctivitis, dry eye syndrome, and postoperative inflammation. Loteprednol's formulation as a non-preserved ocular solution has led to increased patient adherence since it is well-tolerated, especially in sensitive populations. The growing inclination towards preserving patient safety and comfort drives the demand for loteprednol in the corticosteroid eyedrops market. Furthermore, ongoing research into its efficacy in various ocular conditions continues to bolster its popularity among ophthalmologists.

Rimexolone:

Rimexolone is another corticosteroid eyedrop that is primarily utilized for the treatment of postoperative inflammation and other inflammatory ocular conditions. Its unique formulation provides an advantage in terms of reduced side effects and improved patient compliance, particularly when compared to traditional corticosteroids. The growing adoption of rimexolone in clinical practice stems from its effectiveness, particularly in postoperative settings, where it helps alleviate inflammation and pain. The ongoing increase in surgical procedures related to eye health further fuels the consumption of rimexolone-based eyedrops, contributing to the overall growth of the corticosteroid eyedrops market.

By Application

Allergic Conjunctivitis:

Allergic conjunctivitis is a prevalent ocular condition that results from allergic reactions to various environmental allergens. The increasing occurrence of this condition has prompted healthcare providers to prescribe corticosteroid eyedrops to alleviate symptoms such as redness, itching, and swelling. The efficacy of corticosteroids in reducing inflammation and providing quick relief has made them a first-line treatment option for allergic conjunctivitis. As awareness regarding the impact of allergens on eye health grows, the demand for corticosteroid eyedrops specifically targeting allergic conjunctivitis is expected to surge, driving market growth in this application segment.

Dry Eye Syndrome:

Dry eye syndrome, characterized by insufficient tear production, affects a significant portion of the global population, particularly among older adults. Corticosteroid eyedrops have emerged as an effective treatment option for managing this condition, as they help reduce inflammation that can exacerbate symptoms. The rising prevalence of dry eye syndrome, driven by factors such as increased screen time and environmental irritants, has led to a growing demand for corticosteroid therapies. As healthcare providers continue to seek effective solutions for this chronic condition, the segment of corticosteroid eyedrops targeting dry eye syndrome is projected to witness substantial growth in the coming years.

Uveitis:

Uveitis is an inflammatory condition affecting the uvea, which can result in severe vision complications if left untreated. The use of corticosteroid eyedrops is essential for managing uveitis, as they help control inflammation and prevent further ocular damage. The increasing recognition of uveitis and its potential complications among healthcare providers has led to a rise in corticosteroid prescriptions. As research continues to shed light on the effective management of uveitis, the segment focused on corticosteroid eyedrops for this application is expected to experience significant growth as more patients seek timely interventions.

Postoperative Inflammation:

Postoperative inflammation is a common occurrence following ocular surgeries, such as cataract procedures. Corticosteroid eyedrops are routinely prescribed to mitigate inflammation and promote quicker healing post-surgery. The growing number of surgical interventions related to eye health is driving the demand for corticosteroid treatments specifically formulated for postoperative care. With the increasing emphasis on enhancing patient outcomes and reducing recovery times, the application of corticosteroid eyedrops in managing postoperative inflammation is anticipated to continue expanding, contributing to market growth.

Others:

This segment encompasses a variety of additional applications for corticosteroid eyedrops, including managing conditions such as keratitis and ocular surface inflammation. The versatility of corticosteroids in treating diverse ocular conditions facilitates their widespread adoption in clinical practice. As awareness of eye health issues continues to grow, the demand for corticosteroid therapies for less common applications is expected to rise. This segment's growth is supported by ongoing research and development efforts aimed at broadening the therapeutic scope of corticosteroid eyedrops for various ocular conditions.

By Distribution Channel

Hospital Pharmacies:

Hospital pharmacies play a crucial role in the distribution of corticosteroid eyedrops, particularly for patients requiring specialized care. These pharmacies are often equipped to provide tailored medication regimens and offer counseling services to patients regarding proper use. The strong relationship between healthcare providers and hospital pharmacists promotes the effective management of ocular conditions through prescription medications. As more patients seek treatment in hospital settings, the demand for corticosteroid eyedrops distributed through hospital pharmacies is anticipated to grow steadily, bolstered by the ongoing emphasis on patient-centered care.

Retail Pharmacies:

Retail pharmacies serve as a primary point of access for consumers purchasing corticosteroid eyedrops for various ocular conditions. The convenience of retail pharmacies, coupled with the availability of over-the-counter formulations, enhances their appeal among patients seeking immediate relief. As the prevalence of eye-related ailments increases, retail pharmacies are expected to witness a rise in sales of corticosteroid eyedrops. Furthermore, strategic marketing initiatives and collaborations with manufacturers can drive product visibility and availability, further propelling growth in this distribution channel.

Online Pharmacies:

The rise of e-commerce and online pharmacies has revolutionized the way consumers purchase corticosteroid eyedrops. The convenience of ordering medications from home, coupled with discreet delivery options, appeals to patients seeking quick and private access to their eye care products. Online pharmacies often provide competitive pricing and a wide range of product options, making them an attractive choice for consumers. As the trend of online shopping continues to gain momentum, the distribution of corticosteroid eyedrops through online pharmacies is expected to experience significant growth, aligning with changing consumer behaviors and preferences.

By Ingredient Type

Corticosteroid:

The corticosteroid ingredient type is fundamental to the efficacy of eyedrops, as it plays a crucial role in managing inflammation and immune responses. Various corticosteroids, including dexamethasone and prednisolone, are utilized in eyedrop formulations to provide targeted treatment for ocular conditions. The growing demand for corticosteroid-based eyedrops stems from their proven effectiveness in treating a range of eye disorders, driving market growth in this ingredient segment. Continued research into the development of new corticosteroid formulations is expected to enhance treatment options and expand their use in clinical settings.

Preservative:

Preservatives are added to eyedrop formulations to prevent microbial contamination and extend shelf life. The use of preservatives can significantly impact patient compliance, particularly among those with sensitive eyes or pre-existing conditions such as dry eye syndrome. As a result, there is a growing trend towards the development of preservative-free formulations that offer a more comfortable and effective treatment experience. The increasing awareness of the potential side effects associated with preservatives is driving the demand for preservative-free corticosteroid eyedrops, thus shaping this ingredient type's segment.

Stabilizer:

Stabilizers are essential components in eyedrop formulations, ensuring the product's consistency and efficacy. They help maintain the stability of active ingredients and enhance the overall performance of corticosteroid eyedrops. The increasing focus on developing high-quality, stable formulations is expected to drive the demand for stabilizers in the corticosteroid eyedrops market. As advancements in formulation technologies continue to emerge, the incorporation of effective stabilizers will remain a significant priority for manufacturers, ultimately contributing to improved patient outcomes.

Emulsifier:

Emulsifiers are critical in formulating ophthalmic solutions, as they facilitate the mixing of oil and water phases, resulting in a uniform product. The use of emulsifiers in corticosteroid eyedrops enhances the bioavailability and absorption of active ingredients, which is crucial for treating eye conditions effectively. As the market evolves, the demand for innovative emulsifiers that can improve the performance of corticosteroid formulations is anticipated to grow. The emphasis on developing high-quality, effective emulsifiers will play a vital role in shaping the future of the corticosteroid eyedrops market.

Others:

This segment includes various other ingredients utilized in the formulation of corticosteroid eyedrops, such as buffers and tonicity agents. These components are essential for maintaining the stability and compatibility of the solution with the ocular surface, ensuring a comfortable application for patients. As research continues to explore new formulation strategies, the demand for innovative ingredient types in corticosteroid eyedrops is expected to increase. The future landscape will likely be shaped by advancements in ingredient technologies that prioritize patient safety and treatment efficacy.

By Region

The North American region holds a significant share of the global corticosteroid eyedrops market, accounting for approximately 35% of the total market revenue in 2023. The high prevalence of ocular conditions, coupled with advanced healthcare infrastructure, contributes to the robust demand for corticosteroid treatments in this region. Furthermore, the growing awareness of eye health issues among the population and the increasing number of surgical procedures bolster the adoption of corticosteroid eyedrops. With a CAGR of 6.2% projected during the forecast period, the North American market is expected to maintain its dominance and continue driving innovation in corticosteroid therapies.

In Europe, the corticosteroid eyedrops market is also experiencing substantial growth, driven by a rising aging population susceptible to various ocular diseases. The European market accounted for approximately 30% of the global market share in 2023. Increased healthcare spending and a strong emphasis on research and development initiatives are facilitating the introduction of novel corticosteroid formulations. Additionally, the growing presence of key global players in the European market is fostering competition and enhancing product availability. As patients become more aware of treatment options, the European corticosteroid eyedrops market is projected to exhibit a CAGR of 5.5% during the forecast period.

Opportunities

The corticosteroid eyedrops market presents several promising opportunities for growth, particularly in the realm of product innovation and development. With the increasing prevalence of chronic ocular conditions, there is a significant demand for advanced formulations that enhance patient compliance and treatment efficacy. The development of preservative-free formulations is a key focus area, as an increasing number of patients prefer these options due to their improved tolerability and reduced side effects. Additionally, the growth in telemedicine and online healthcare has opened new avenues for the distribution of corticosteroid eyedrops, allowing manufacturers to reach a broader audience. As healthcare providers continue to prioritize patient-centered care, the market can expect a surge in the adoption of innovative corticosteroid therapies that meet evolving patient needs.

Moreover, the growing emphasis on preventive care and early intervention in eye health presents substantial opportunities for the corticosteroid eyedrops market. Increasing awareness of the importance of regular eye examinations and preventive measures can drive demand for corticosteroid treatments, particularly among high-risk populations. Collaborative efforts between healthcare professionals, regulatory bodies, and educational organizations can enhance public knowledge about ocular health and the role of corticosteroid therapies in managing eye conditions. By tapping into these opportunities, stakeholders within the corticosteroid eyedrops market can position themselves for sustained growth and contribute to improving patient outcomes.

Threats

Despite the positive outlook for the corticosteroid eyedrops market, several threats could hinder its growth trajectory. One significant threat is the increasing competition from alternative therapies, including non-steroidal anti-inflammatory medications and innovative biologics that offer similar benefits without the risk of corticosteroid-related side effects. As patients become more informed and proactive about their treatment options, there is a growing likelihood that some may opt for alternatives that carry fewer risks. Additionally, the regulatory landscape surrounding pharmaceutical products is constantly evolving, and stringent regulations can pose challenges in terms of product approvals and market access. Manufacturers must remain vigilant and adaptable to navigate these challenges, ensuring compliance with changing regulatory requirements.

Furthermore, the rising awareness of the potential side effects associated with long-term corticosteroid use can lead to hesitance among both patients and healthcare providers regarding their prescription. Concerns about intraocular pressure elevation, cataract formation, and other adverse effects can impact the overall acceptance of corticosteroid therapies in clinical practice. Education and outreach efforts to inform patients and healthcare providers about the safe and effective use of corticosteroid eyedrops will be crucial to mitigating these threats and preserving market growth.

Competitor Outlook

• Allergan, Inc.
• Novartis AG
• Pfizer Inc.
• Merck & Co., Inc.
• Hoffmann-La Roche AG
• Valeant Pharmaceuticals International, Inc.
• Akorn, Inc.
• Ocular Therapeutix, Inc.
• Bausch Health Companies Inc.
• Sun Pharmaceutical Industries Ltd.
• Alimera Sciences, Inc.
• Santen Pharmaceutical Co., Ltd.
• Eyevance Pharmaceuticals LLC
• Hikma Pharmaceuticals PLC
• Teva Pharmaceutical Industries Ltd.

The competitive landscape of the corticosteroid eyedrops market is characterized by the presence of several key players actively engaged in product development, distribution, and marketing. Major pharmaceutical companies are investing significantly in research and development to create innovative formulations that address patient needs while maintaining high-quality standards. The emphasis on developing preservative-free options and advanced delivery systems is reshaping the competitive dynamics in this market. Companies are also exploring strategic partnerships and collaborations to enhance their product offerings and extend their market reach, thereby fostering competition and stimulating growth within the corticosteroid eyedrops segment.

Allergan, Inc., a leader in the ophthalmic pharmaceutical market, has established a strong presence with its extensive portfolio of corticosteroid eyedrops. The company is known for its innovative products, such as Dexamethasone and Loteprednol, which cater to various ocular conditions. Allergan's commitment to research and development enables it to stay at the forefront of the industry, continuously enhancing patient care through new and improved formulations. Similarly, Novartis AG is another major player focused on expanding its presence in the corticosteroid market. The company's diverse product line, coupled with its ongoing efforts to enhance treatment options, positions it favorably for long-term success.

Furthermore, Santen Pharmaceutical Co., Ltd. is recognized for its dedication to ophthalmology and offers a comprehensive range of corticosteroid eyedrops. The company’s focus on research and development, particularly in the field of preservative-free formulations, aligns with the growing demand for safer and more effective treatment options. With an emphasis on patient outcomes, Santen aims to provide innovative solutions that meet the evolving needs of healthcare providers and patients alike. As competition intensifies, companies will continue to adapt their strategies, emphasizing product differentiation, patient education, and enhanced distribution channels to capture a larger market share in the corticosteroid eyedrops market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Akorn, Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Novartis AG
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Pfizer Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Allergan, Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Merck & Co., Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Hoffmann-La Roche AG
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Alimera Sciences, Inc.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Ocular Therapeutix, Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Hikma Pharmaceuticals PLC
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Bausch Health Companies Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Eyevance Pharmaceuticals LLC
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Santen Pharmaceutical Co., Ltd.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Sun Pharmaceutical Industries Ltd.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Teva Pharmaceutical Industries Ltd.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Valeant Pharmaceuticals International, Inc.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Corticosteroid Eyedrops Sales Market, By Application
    • 6.1.1 Allergic Conjunctivitis
    • 6.1.2 Dry Eye Syndrome
    • 6.1.3 Uveitis
    • 6.1.4 Postoperative Inflammation
    • 6.1.5 Others
  • 6.2 Corticosteroid Eyedrops Sales Market, By Product Type
    • 6.2.1 Dexamethasone
    • 6.2.2 Prednisolone
    • 6.2.3 Fluorometholone
    • 6.2.4 Loteprednol
    • 6.2.5 Rimexolone
  • 6.3 Corticosteroid Eyedrops Sales Market, By Ingredient Type
    • 6.3.1 Corticosteroid
    • 6.3.2 Preservative
    • 6.3.3 Stabilizer
    • 6.3.4 Emulsifier
    • 6.3.5 Others
  • 6.4 Corticosteroid Eyedrops Sales Market, By Distribution Channel
    • 6.4.1 Hospital Pharmacies
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Corticosteroid Eyedrops Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Corticosteroid Eyedrops Sales market is categorized based on

By Product Type

• Dexamethasone
• Prednisolone
• Fluorometholone
• Loteprednol
• Rimexolone

By Application

• Allergic Conjunctivitis
• Dry Eye Syndrome
• Uveitis
• Postoperative Inflammation
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Ingredient Type

• Corticosteroid
• Preservative
• Stabilizer
• Emulsifier
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Allergan, Inc.
• Novartis AG
• Pfizer Inc.
• Merck & Co., Inc.
• Hoffmann-La Roche AG
• Valeant Pharmaceuticals International, Inc.
• Akorn, Inc.
• Ocular Therapeutix, Inc.
• Bausch Health Companies Inc.
• Sun Pharmaceutical Industries Ltd.
• Alimera Sciences, Inc.
• Santen Pharmaceutical Co., Ltd.
• Eyevance Pharmaceuticals LLC
• Hikma Pharmaceuticals PLC
• Teva Pharmaceutical Industries Ltd.